Eversept Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Eversept Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-54,500	Closed	-$10.6M	–	124
2021 Q2	$11M	Buy	+54,500	New	+$11.4M	0.73%	35
2020 Q1	–	Sell	-73,009	Closed	-$16M	–	79
2019 Q4	$16M	Buy	73,009 +22,100	+43%	+$4.47M	2.82%	13
2019 Q3	$8.63M	Sell	50,909 -6,940	-12%	-$1.23M	2.68%	10
2019 Q2	$10.6M	Buy	57,849 +19,620	+51%	+$3.43M	2.97%	11
2019 Q1	$7.03M	Buy	38,229 +1,737	+5%	+$321K	2.05%	14
2018 Q4	$6.05M	Sell	36,492 -11,600	-24%	-$2.01M	3.27%	8
2018 Q3	$9.27M	Buy	48,092 +13,270	+38%	+$2.36M	4.07%	9
2018 Q2	$5.92M	Sell	34,822 -10,000	-22%	-$1.55M	2.71%	14
2018 Q1	$7.31M	Sell	44,822 -13,300	-23%	-$2.17M	3.39%	13
2017 Q4	$8.71M	Buy	+58,122	New	+$8.61M	5.01%	5

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eversept Partners's VRTX Position: Q3 2021 in Review

Eversept Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 54,500 shares — an estimated $10.6M sold.

Eversept Partners first reported a position in VRTX in Q4 2017 and held it in 10 quarters. The position peaked at $16M in Q4 2019. 934 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Eversept Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Eversept Partners sold 54,500 Vertex Pharmaceuticals shares in Q3 2021, an estimated $10.6M.
Eversept Partners first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Eversept Partners's Vertex Pharmaceuticals position peaked at $16M in Q4 2019.
934 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.